drugset / Trial / NCT02954445

A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies

NCT02954445 ↗

Phase 1/2 Unknown 45 enrolled Southwest Hospital, China
NaSingle-groupOpen-labelTreatment

Summary

The overall purpose of this study is to explore the therapeutic effect of BCMA-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of B-cell derived malignancies.

Timeline

Start
2016-10
Primary completion
2019-10
Completion
2020-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Anti-BCMA-CAR-transduced T cells Cell therapy — —